NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212
NTHI•NeOnc Technologies will meet in person with the FDA on Nov. 17, 2026, to discuss NEO212’s Phase 2 study design, dose selection, endpoints and evidence for a future marketing application. The company will also seek feedback on whether its proposed development plan could support accelerated approval.
1. FDA meeting planned
NeOnc Technologies will hold an in-person FDA End-of-Phase 1 Type B meeting on Nov. 17, 2026, for NEO212. The discussion will cover Phase 2 study design, dose selection, endpoints and evidence needed to support a future marketing application, as well as whether the proposed development plan could support an accelerated approval pathway.
